Tyler Engel
FSA, MAAA
Principal and Consulting Actuary
New York, NY, US
Tyler Engel is a principal and consulting actuary with the New York office of Milliman. He joined the firm in 2012.
Experience
Tyler provides a variety of skills, intelligence, and market strategy with a specialty in prescription drugs to a broad range of clients, including health plans, hospital systems, pharmaceutical companies, medical device manufacturers, healthcare industry trade organizations, disease and medical management vendors, and other healthcare providers.
For over a decade, he has helped these healthcare stakeholders address many new and arising challenges in the following areas:
- Market access strategy
- Medicare Part D filings
- Health Economics and Outcomes Research (HEOR)
- Evaluation of the cost effectiveness of care management programs
- Policy research and analysis
- Impact of the Inflation Reduction Act on Medicare Part D
Publications and Presentations
Tyler is the editor and co-author of several publicly available white papers and peer review journal publications focused on health cost outcomes research and public policy.
Professional Designations
- Fellow, Society of Actuaries
- Member, American Academy of Actuaries
Education
- BS, Mathematics and Actuarial Science, University of Connecticut
Publications
Read their latest work
Article
Utilization and reimbursement of COVID-19 molecular multiplex testing in the commercial health insurance market
24 July 2024 - by Gabriela Dieguez, Tyler Engel, James Burke
We examined utilization and reimbursement patterns of COVID-19 tests in the commercially-insured population.
Article
The shifting Medicare landscape: Results from 2024 open enrollment
02 May 2024 - by Samantha D’Anna, Tyler Engel, Katherine M. Holcomb
2024 brings significant changes to the Medicare Part D program, resulting in larger-than-average shifts in member enrollment.
Article
CMS Cell and Gene Therapy Access Model
25 April 2024 - by Palak Desai, Jessica Naber, Prachi Bhatt, Tyler Engel
CMS’s Cell and Gene Therapy Access Model offers Medicaid programs increased access to the treatment while addressing complexities and financial uncertainties.
Article
Part D redesign under the Inflation Reduction Act
30 August 2023 - by Corey Berger, Tyler Engel, Todd Wanta
We examine potential ramifications of the Inflation Reduction Act, which may drive the biggest changes in prescription drug coverage since Medicare Part D.
Article
Site of Service and Cost Dispersion of Infused Drugs
11 December 2019 - by Gabriela Dieguez, Tyler Engel, Nathaniel Jacobson
This paper examines the cost dispersion of one infused disease-modifying therapies treatment, ocrelizumab, by site of service for patients with commercial insurance, a major insurance segment for multiple sclerosis patients.
Article
The cost impact to Medicare of shifting treatment of worsening heart failure from inpatient to outpatient management settings
23 January 2019 - by Tyler Engel, Kate Fitch, Jocelyn Lau
This study estimates the cost impact to the Medicare fee-for-service population associated with shifting the treatment of a portion of worsening heart failure cases from the inpatient hospital setting to outpatient settings.
Article
The cost burden of worsening heart failure in the Medicare fee for service population: An actuarial analysis
03 April 2017 - by Tyler Engel, Kate Fitch, Jocelyn Lau
This report identifies the rate and costs of heart failure (HF) admissions, the costs in the 30 days after HF admissions, and the percentage of HF admissions that are readmissions.
Article
Real-world insights and economic considerations in type 2 diabetes
27 March 2017 - by Tyler Engel, Kate Fitch, Bruce S. Pyenson
This paper presents patterns of hemoglobin A1c levels and diabetes medication adherence among people with type 2 diabetes mellitus based on real-world data from 2012 to 2014.
Article
Cardiovascular event incidence and cost in type 2 diabetes: A commercial and Medicare claim based actuarial analysis
10 August 2016 - by Tyler Engel, Kate Fitch
An analysis to identify the annual rate and cost of cardiovascular (CV) events in patients with type 2 diabetes mellitus (T2DM) and the contribution of these CV events to both T2DM annual costs as well as total Medicare fee-for-service and commercially insured population annual costs.
Article
Cost differences between open and minimally invasive surgery
06 August 2016 - by Andrew Bochner, Tyler Engel, Kate Fitch
This study analyzes the difference in payer costs between minimally invasive surgery and open surgery in a commercial population for four commonly performed elective surgical procedures.